Sponsor content
49 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEOZA fezolinetant 45 mg film coated tablet blister pack.
-
Australian public assessment report (AusPar)Veoza (fezolinetant) has been approved for the treatment of moderate to severe hot flashes associated with menopause
-
Prescription medicine decision summaryVeoza (fezolinetant) has been approved for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.
-
Prescription medicine registrationActive ingredients: fezolinetant.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 30 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 20 mg powder for injection vial.
-
Designation or determinationOrphan drug
-
Australian public assessment report (AusPar)AusPAR for Padcev (Enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed receptor-1 or programmed death-ligand-1 inhibitor.
-
Prescription medicine decision summaryPadcev (enfortumab vedotin) is approved to treat adult patients with locally advanced or metastatic urothelial cancer.
-
Prescription medicine registrationActive ingredients: enfortumab vedotin.